Peter Lawson
Stock Analyst at Barclays
(1.19)
# 3,484
Out of 4,843 analysts
109
Total ratings
33.33%
Success rate
-15.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Peter Lawson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MGNX MacroGenics | Maintains: Overweight | $8 → $3 | $1.38 | +117.39% | 9 | May 14, 2025 | |
| FATE Fate Therapeutics | Maintains: Overweight | $10 → $2 | $1.21 | +65.29% | 4 | May 14, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Underweight | $1 → $0.46 | $0.29 | +57.26% | 3 | May 14, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Overweight | $5 → $10 | $4.20 | +138.10% | 3 | May 13, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Overweight | $5 → $4 | $1.75 | +128.57% | 7 | May 12, 2025 | |
| XNCR Xencor | Maintains: Underweight | $22 → $6 | $8.00 | -25.00% | 2 | May 8, 2025 | |
| KURA Kura Oncology | Maintains: Overweight | $32 → $11 | $5.68 | +93.66% | 1 | May 2, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $32 → $16 | $7.20 | +122.22% | 8 | May 2, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Overweight | $40 → $15 | $8.22 | +82.48% | 2 | May 1, 2025 | |
| SWTX SpringWorks Therapeutics | Downgrades: Equal-Weight | $63 → $47 | $46.72 | +0.61% | 4 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $29 → $14 | $8.93 | +56.77% | 7 | Apr 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $3 | $1.44 | +108.33% | 5 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $3 | $1.44 | +108.33% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $4 | $1.52 | +163.16% | 1 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $29 | $43.04 | -32.62% | 5 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $60 | $39.40 | +52.28% | 3 | Sep 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $17 | $3.00 | +466.67% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $33 | $10.54 | +213.09% | 4 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $66 | $36.50 | +80.82% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $75 → $105 | $101.35 | +3.60% | 10 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $31 | $10.63 | +191.63% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $8.98 | +89.31% | 3 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $13 | $2.22 | +485.59% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $0.89 | +464.40% | 4 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3.5 | $2.65 | +32.08% | 4 | Jul 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $355 → $365 | $82.24 | +343.82% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $46 | $32.09 | +43.35% | 2 | Oct 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.72 | +4,040.79% | 1 | Mar 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $17 → $45 | $1.72 | +2,516.28% | 2 | Jan 23, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $16 → $45 | $36.29 | +24.00% | 2 | Jan 23, 2018 |
MacroGenics
May 14, 2025
Maintains: Overweight
Price Target: $8 → $3
Current: $1.38
Upside: +117.39%
Fate Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $10 → $2
Current: $1.21
Upside: +65.29%
Adaptimmune Therapeutics
May 14, 2025
Maintains: Underweight
Price Target: $1 → $0.46
Current: $0.29
Upside: +57.26%
Karyopharm Therapeutics
May 13, 2025
Maintains: Overweight
Price Target: $5 → $10
Current: $4.20
Upside: +138.10%
Iovance Biotherapeutics
May 12, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $1.75
Upside: +128.57%
Xencor
May 8, 2025
Maintains: Underweight
Price Target: $22 → $6
Current: $8.00
Upside: -25.00%
Kura Oncology
May 2, 2025
Maintains: Overweight
Price Target: $32 → $11
Current: $5.68
Upside: +93.66%
Arvinas
May 2, 2025
Maintains: Overweight
Price Target: $32 → $16
Current: $7.20
Upside: +122.22%
Bicycle Therapeutics
May 1, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $8.22
Upside: +82.48%
SpringWorks Therapeutics
Apr 28, 2025
Downgrades: Equal-Weight
Price Target: $63 → $47
Current: $46.72
Upside: +0.61%
Apr 23, 2025
Maintains: Overweight
Price Target: $29 → $14
Current: $8.93
Upside: +56.77%
Apr 2, 2025
Maintains: Equal-Weight
Price Target: $11 → $3
Current: $1.44
Upside: +108.33%
Mar 7, 2025
Maintains: Overweight
Price Target: $14 → $3
Current: $1.44
Upside: +108.33%
Feb 27, 2025
Maintains: Overweight
Price Target: $9 → $4
Current: $1.52
Upside: +163.16%
Feb 13, 2025
Maintains: Equal-Weight
Price Target: $25 → $29
Current: $43.04
Upside: -32.62%
Sep 27, 2024
Maintains: Overweight
Price Target: $54 → $60
Current: $39.40
Upside: +52.28%
Sep 10, 2024
Maintains: Overweight
Price Target: $14 → $17
Current: $3.00
Upside: +466.67%
Aug 15, 2024
Maintains: Overweight
Price Target: $32 → $33
Current: $10.54
Upside: +213.09%
Aug 9, 2024
Maintains: Overweight
Price Target: $92 → $66
Current: $36.50
Upside: +80.82%
Jul 29, 2024
Maintains: Equal-Weight
Price Target: $75 → $105
Current: $101.35
Upside: +3.60%
Jul 15, 2024
Maintains: Overweight
Price Target: $20 → $31
Current: $10.63
Upside: +191.63%
Jun 7, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $8.98
Upside: +89.31%
May 24, 2024
Maintains: Overweight
Price Target: $18 → $13
Current: $2.22
Upside: +485.59%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $0.89
Upside: +464.40%
Jul 7, 2022
Maintains: Overweight
Price Target: $7 → $3.5
Current: $2.65
Upside: +32.08%
Aug 6, 2021
Maintains: Underweight
Price Target: $355 → $365
Current: $82.24
Upside: +343.82%
Oct 22, 2020
Upgrades: Overweight
Price Target: $46
Current: $32.09
Upside: +43.35%
Mar 4, 2020
Initiates: Overweight
Price Target: $30
Current: $0.72
Upside: +4,040.79%
Jan 23, 2018
Upgrades: Buy
Price Target: $17 → $45
Current: $1.72
Upside: +2,516.28%
Jan 23, 2018
Upgrades: Buy
Price Target: $16 → $45
Current: $36.29
Upside: +24.00%